Actionable news
0
All posts from Actionable news
Actionable news in LPTN: Lpath, Inc.,

Lpath Appoints Gary Atkinson Interim Chief Executive Officer

The following excerpt is from the company's SEC filing.

SAN DIEGO, September 29, 2015

Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpaths chief financial officer.

Mr. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer. He also previously served as vice president of finance at Isis Pharmaceuticals, and as a fin ancial consultant to Ichor Medical Systems. Earlier in his career, Mr. Atkinson served as the corporate controller at Loral Aerospace Corporation and as the director of financial planning at Cubic Corporation. Mr. Atkinson began his career at Ernst and Young. He is a graduate of Brigham Young University.

In an increased capacity, Gary will lead our organization to advance Lpaths portfolio of differentiated, bioactive lipid-targeted drug candidates, and capitalize upon our assets whether independently or through collaborations to realize value for our shareholders and our company, said Daniel Petree, chairman of Lpaths board of directors.

The Lpath team is optimistic about the opportunities inherent in our technology platform and drug candidates, said Mr. Atkinson. In my expanded...


More